MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

MDT

100.66

-0.05%↓

133.89

-1.33%↓

VEEV

217.29

-0.15%↓

HQY

82.83

-0.01%↓

NEOG

10.35

+1.07%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Отворен

4.53 -4.83

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.5

Максимум

4.73

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	11M 31M
Предишно отваряне	9.36
Предишно затваряне	4.53

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.01.2026 г., 23:07 ч. UTC

Печалби

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27.01.2026 г., 21:27 ч. UTC

Печалби

Texas Instruments 4Q Sales Rise, Profit Falls

27.01.2026 г., 23:55 ч. UTC

Пазарно говорене

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27.01.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.01.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27.01.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27.01.2026 г., 23:20 ч. UTC

Печалби

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27.01.2026 г., 23:20 ч. UTC

Печалби

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27.01.2026 г., 23:19 ч. UTC

Печалби

SK Innovation Posts Net Loss for Second Consecutive Year

27.01.2026 г., 23:19 ч. UTC

Печалби

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27.01.2026 г., 23:18 ч. UTC

Печалби

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27.01.2026 г., 23:18 ч. UTC

Печалби

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27.01.2026 г., 23:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

27.01.2026 г., 23:11 ч. UTC

Пазарно говорене

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27.01.2026 г., 23:07 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27.01.2026 г., 22:17 ч. UTC

Пазарно говорене

U.S. Dollar Slips Following Trump Comments -- Market Talk

27.01.2026 г., 22:06 ч. UTC

Печалби

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27.01.2026 г., 21:51 ч. UTC

Печалби

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

27.01.2026 г., 21:43 ч. UTC

Печалби

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27.01.2026 г., 21:41 ч. UTC

Печалби

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27.01.2026 г., 21:38 ч. UTC

Печалби

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27.01.2026 г., 21:32 ч. UTC

Печалби

Ampol: Modest Profit From F&I International in 2025

27.01.2026 г., 21:32 ч. UTC

Печалби

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27.01.2026 г., 21:31 ч. UTC

Печалби

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27.01.2026 г., 21:31 ч. UTC

Печалби

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27.01.2026 г., 21:30 ч. UTC

Печалби

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27.01.2026 г., 21:29 ч. UTC

Печалби

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27.01.2026 г., 21:29 ч. UTC

Печалби

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27.01.2026 г., 21:28 ч. UTC

Печалби

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.